NRIX · Nurix Therapeutics, Inc.
$25.34
-0.67% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$2B
Trailing P/E
10.4
Forward P/E
-19.9
Dividend yield
0.0%
Beta
1.82
Avg volume
2M
Employees
0K
Daily Change %
-0.67%
5 Days Change
4.46%
10 Days Change
15.27%
30 Days Change
6.83%
60 Days Change
-2.89%
Month to Day Change
9.30%
Year to Day Change
34.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NRIX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
RBC Capital
Outperform$35.00
+38.1% vs priceMorgan Stanley
Overweight$38.00
+50.0% vs priceUBS
Buy$31.00
+22.3% vs priceJefferies
Buy$45.00
+77.6% vs priceWells Fargo
Overweight$25.00
-1.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | HC Wainwright & Co. | Maintains | Buy | $34.00 → $36.00 |
| 2026-10-13 | RBC Capital | Maintains | Outperform | $36.00 → $35.00 |
| 2026-10-13 | Oppenheimer | Maintains | Outperform | $28.00 → $32.00 |
| 2026-10-13 | Truist Securities | Maintains | Buy | $34.00 → $33.00 |
| 2026-10-13 | Baird | Maintains | Outperform | $33.00 → $36.00 |
| 2026-10-13 | Needham | Reiterates | Buy | $34.00 |
| 2026-08-10 | RBC Capital | Maintains | Outperform | $33.00 → $36.00 |
| 2026-08-04 | Needham | Reiterates | Buy | $34.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 1.2% above the 50-day MA ($25.03).
- bullish: Price vs 200-day MA: Trading 26.8% above the 200-day MA ($19.98).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.38) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($10.40) and high ($27.79).
NRIX Price Chart
Loading chart for NRIX…
Fundamentals
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.